Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) FCF Margin (2016 - 2025)

Plus Therapeutics has reported FCF Margin over the past 13 years, most recently at 461.23% for Q4 2025.

  • Quarterly FCF Margin fell 37469.0% to 461.23% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 399.81% through Dec 2025, down 21609.0% year-over-year, with the annual reading at 399.81% for FY2025, 21609.0% down from the prior year.
  • FCF Margin was 461.23% for Q4 2025 at Plus Therapeutics, down from 183.04% in the prior quarter.
  • Over five years, FCF Margin peaked at 54.75% in Q3 2023 and troughed at 5828.77% in Q3 2022.
  • The 4-year median for FCF Margin is 262.6% (2024), against an average of 825.26%.
  • Year-over-year, FCF Margin surged 577402bps in 2023 and then tumbled -37469bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 1859.84% in 2022, then surged by 92bps to 146.46% in 2023, then surged by 41bps to 86.54% in 2024, then tumbled by -433bps to 461.23% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's FCF Margin are 461.23% (Q4 2025), 183.04% (Q3 2025), and 417.63% (Q2 2025).